Isis Pharma and Glaxo Ink $1.5B Development Deal

Isis Pharmaceuticals will be working with GlaxoSmithKline to develop treatments for rare diseases. While a lucrative deal for Isis–resulting in almost $1.5 billion in future payments–this collaboration could take critical steps towards treating rare and serious diseases. Under terms of the agreement, Isis will manage early research and development of drug candidates.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail